Details

Autor(en) / Beteiligte

• Chen, Guo-Feng
• Wei, Lai
• Chen, Jing
• Duan, Zhong-Ping
• Dou, Xiao-Guang
• Xie, Qing
• Zhang, Wen-Hong
• Lu, Lun-Gen
• Fan, Jian-Gao
• Cheng, Jun
• Wang, Gui-Qiang
• Ren, Hong
• Wang, Jiu-Ping
• Yang, Xing-Xiang
• Jia, Zhan-Sheng
• Fu, Qing-Chun
• Wang, Xiao-Jin
• Shang, Jia
• Zhang, Yue-Xin
• Han, Ying
• Du, Ning
• Shao, Qing
• Ji, Dong
• Li, Fan
• Li, Bing
• Liu, Jia-Liang
• Niu, Xiao-Xia
• Wang, Cheng
• Wu, Vanessa
• Wong, April
• Wang, Yu-Dong
• Hou, Jin-Lin
• Jia, Ji-Dong
• Zhuang, Hui
• Lau, George
• Kanda, Tatsuo

Titel

Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data

Ist Teil von

• PloS one, 2016-06, Vol.11 (6), p.e0155934-e0155934

Ort / Verlag

United States: Public Library of Science

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries. We evaluated cost-effectiveness of sofosbuvir/ledipasvir for 12 weeks compared with a 48-week pegIFN-RBV regimen in Chinese patients with genotype 1b HCV infection by economic regions. A decision analytic Markov model was developed to estimate quality-adjusted-life-years, lifetime cost of HCV infection and incremental cost-effectiveness ratios (ICERs). SVR rates and direct medical costs were obtained from real-world data. Parameter uncertainty was assessed by one-way and probabilistic sensitivity analyses. Threshold analysis was conducted to estimate the price which can make the regimen cost-effective and affordable. Sofosbuvir/ledipasvir was cost-effective in treatment-experienced patients with an ICER of US$21,612. It varied by economic regions. The probability of cost-effectiveness was 18% and 47% for treatment-naive and experienced patients, and it ranged from 15% in treatment-naïve patients in Central-China to 64% in treatment-experienced patients in Eastern-China. The price of 12-week sofosbuvir/ledipasvir treatment needs to be reduced by at least 81% to US$18,185 to make the regimen cost-effective in all patients at WTP of one time GDP per capita. The price has to be US$105 to make the regimen affordable in average patients in China. Sofosbuvir/ledipasvir regimen is not cost-effective in most Chinese patients with genotype 1b HCV infection. The results vary by economic regions. Drug price of sofosbuvir/ledipasvir needs to be substantially reduced when entering the market in China to ensure the widest accessibility.